BIOCORP Reports H1 2021 Results - Seite 2

June 30^th, 2021

June 30^th, 2020

Sales

3 593

3 809

Other operating income

291

-19

Total operating income

3 884

3 791

Net operating income

-1 330

-961

Net financial income

-50

-79

Exceptional item

30

181

Research Tax Credit & Innovation Tax Credit

-126

-81

Net Profit

-1 224

-778

Highlights of the first half of 2021

• Mallya's technological integration with digital applications developed by the Spanish company SocialDiabetes and the Taiwanese company Heath2Sync: opening new high-potential markets with more than 850,000 users.
• Co-development agreement with Diabeloop in personalized diabetes management: integration of automated solutions with the market of insulin smart pens.
• Launch of Mallya in pharmacies by Roche Diabetes Care France: solution to better the daily life of diabetic patients.

Post-period key factors

• Partnership agreement with Merck for the development of a specific version of the Mallya device in the field of Human Growth Hormone (upfront of €3 million).
• Major global contract with Novo Nordisk, the major player in diabetes worldwide, to develop a specific version of Mallya for their pens.

Objectives & outlook for the second half of 2021

After a first half of 2021 still marked by the COVID context and during which Mallya's first sales have not yet produced their effects, the September 2021 announcements show an acceleration of BIOCORP's activities, both in terms of research and expansion of its product range.

• Connected devices: BIOCORP is intensifying the development of new generations of Mallya for all its industrial partners (Sanofi, Roche, and Novo Nordisk). The favorable impact of Mallya sales on the Company's revenues will take full effect in 2022. In parallel, BIOCORP is actively preparing the first applications of Injay, a pre-filled syringe that automatically collects injection data.
• Traditional packaging activity: the Company intends to pursue its opportunistic strategy for small and medium-sized production runs on its entire range of packaging products (cannulas, vials, caps, pipettes…).

⁽¹⁾ The Board of Directors of BIOCORP, meeting on September 24, 2021, approved the accounts for the first half of 2021. During this Board meeting, Émilie Gardette resigned from her position as director. Éric Dessertenne, Chief Executive Officer of BIOCORP, was co-opted as a replacement. His co-option will be submitted for ratification at the next General Meeting of the Company.